Cancer Research Technology
Log in Register
Menu

SK-MEL-93 DX3 beta6-puro Cell Line
RECENTLY UPDATED

Info

Catalogue Number 151625
Antigen/Gene or Protein Targets Beta 6 integrin
Parental Line
RECENTLY UPDATED
SK-MEL-93 DX3
Synonyms
RECENTLY UPDATED
DX3beta6-puro
Host Human
Disease Keywords Melanoma
Model Knock-Out
Relevance
RECENTLY UPDATED
SK-MEL-93 DX3 puro-beta6 Cell Line is a melanoma cell line endogenously expressing a range of integrins, but not beta 6. The use of SK-MEL-93 DX3-puro/beta6 as a matched pair with the SK-MEL-93 DX3-puro cell line is a useful tool for studying beta 6 function or specificity of agents that interfere with beta 6.
Production Details
RECENTLY UPDATED
As described in Hausner et al. Cancer Research (2007) Vol 67, p7833-7840. The human melanoma cell line SK-MEL-93 DX3 was infected with pBabe retroviruses encoding puromycin resistance or, in addition, cDNA for human integrin beta 6. Cells were selected in puromycin (1.25 ug/mL) followed by magnetic bead sorting, using 10D5 (mouse anti-avh6; Chemicon International), according to the manufacturer’s instructions (Dynal; Invitrogen). When growing these lines the antibiotic does not have to be there all the time. The avb6 expression can drift so recipients must check by flow cytometery after they have been in continuous passage, at least once a month. Use the above magnetic beads to re-select when this happens.
Research Area
RECENTLY UPDATED
Adhesion, Cancer, Cell Signaling & Signal Transduction, Drug Discovery & Development
Growth/Phenotype Keywords DX3 melanoma cell line stably transfected with the integrin beta 6
Recommended Growing Conditions DMEM + 10%FCS/1.25ug/ml puromycin. Antibiotic is not necessary all the time.
Notes
RECENTLY UPDATED
Useful model for studying the function and activity of beta 6 integrin when used as a matched pair with the parent SK-MEL-93 DX3 line. SK-MEL-93 DX3 cells endogenously express a variety of integrins, but not beta 6. These cell lines have been used to validate the activity and selectivity of AvB6 binding peptides.
Cellosaurus ID CVCL_1D33

References

There are 6 reference entries for this reagent.

View All References

References: 6 entries
RECENTLY UPDATED

Hausner et al. 2009. Cancer Res. 69(14):5843-50. PMID: 19549907.

Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model.

Europe PMC ID: 19549907

Hausner et al. 2009. Mol Imaging. 8(2):111-21. PMID: 19397856.

Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an alphavbeta6-specific peptide.

Europe PMC ID: 19397856

Hausner et al. 2007. Cancer Res. 67(16):7833-40. PMID: 17699789.

Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography.

Europe PMC ID: 17699789


Add a reference

References: 6 entries
RECENTLY UPDATED

Hausner et al. 2009. Cancer Res. 69(14):5843-50. PMID: 19549907.

Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model.

Hausner et al. 2009. Mol Imaging. 8(2):111-21. PMID: 19397856.

Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an alphavbeta6-specific peptide.

Hausner et al. 2007. Cancer Res. 67(16):7833-40. PMID: 17699789.

Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor